review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Sarah Spiegel | Q20950329 |
P2093 | author name string | Sheldon Milstien | |
Kazuaki Takabe | |||
Steven W Paugh | |||
P2860 | cites work | EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue | Q22004152 |
Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate | Q22010773 | ||
Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform | Q22253469 | ||
Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes | Q24290103 | ||
Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling | Q24292094 | ||
Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization | Q24294548 | ||
Molecular machinery for non-vesicular trafficking of ceramide | Q24302195 | ||
Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases | Q24311877 | ||
Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1 | Q24314828 | ||
Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2 | Q24314898 | ||
Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells | Q24319142 | ||
Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide | Q24337032 | ||
Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling | Q24337047 | ||
Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation | Q24629370 | ||
Role of ABCC1 in export of sphingosine-1-phosphate from mast cells | Q24671687 | ||
Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement | Q24671831 | ||
Characterization of a novel sphingosine 1-phosphate receptor, Edg-8 | Q28143704 | ||
Sphingosine kinase: a mediator of vital cellular functions | Q28185880 | ||
The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha | Q28190914 | ||
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature | Q28201589 | ||
PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA) | Q28215068 | ||
The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind | Q28217600 | ||
Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts | Q28254794 | ||
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
Molecular cloning and functional characterization of murine sphingosine kinase | Q28281335 | ||
Essential role for sphingosine kinases in neural and vascular development | Q28505987 | ||
Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720 | Q28512961 | ||
Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis | Q28566922 | ||
Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS | Q28567378 | ||
IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses | Q28586614 | ||
An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability | Q28591860 | ||
Characterization of murine sphingosine-1-phosphate phosphohydrolase | Q28592202 | ||
Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3 | Q28593745 | ||
EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration | Q28594391 | ||
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 | ||
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 | Q29619644 | ||
Sphingosine-1-phosphate: an enigmatic signalling lipid | Q29620563 | ||
Sphingosine 1-phosphate analogs as receptor antagonists | Q30435361 | ||
Discovery and evaluation of inhibitors of human sphingosine kinase | Q31004970 | ||
Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1. | Q31626065 | ||
Functions of a new family of sphingosine-1-phosphate receptors | Q31640177 | ||
Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility | Q32075112 | ||
Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors | Q32144510 | ||
Sphingosine kinase: biochemical and cellular regulation and role in disease | Q36439269 | ||
Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation | Q36530007 | ||
Regulation and functional roles of sphingosine kinases | Q36715339 | ||
Tipping the gatekeeper: S1P regulation of endothelial barrier function | Q36727643 | ||
Autocrine and paracrine roles of sphingosine-1-phosphate | Q36955411 | ||
Finding a way out: lymphocyte egress from lymphoid organs | Q37008187 | ||
Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice | Q37648373 | ||
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation | Q38411404 | ||
Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform | Q39740344 | ||
Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. | Q39751424 | ||
Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin | Q40059172 | ||
Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells | Q40078636 | ||
Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. | Q40104489 | ||
The immunomodulator FTY720 is phosphorylated and released from platelets | Q40123102 | ||
S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells | Q40161177 | ||
Sphingosine kinase type 2 activation by ERK-mediated phosphorylation | Q40168870 | ||
Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation | Q40267989 | ||
Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells | Q40271531 | ||
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin | Q33504255 | ||
A lymphoid tissue-specific receptor, EDG6, with potential immune modulatory functions mediated by extracellular lysophospholipids. | Q33681343 | ||
The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. | Q33770369 | ||
S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. | Q33878942 | ||
Physiology and pathophysiology of sphingolipid metabolism and signaling | Q33930354 | ||
Sphingolipid transport in eukaryotic cells. | Q33944782 | ||
Sphingosine 1-phosphate, a key cell signaling molecule | Q34128454 | ||
De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway | Q34128457 | ||
Sphingosine 1-phosphate: synthesis and release | Q34233389 | ||
Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite | Q34339041 | ||
Sphingosine kinase 1 is an intracellular effector of phosphatidic acid | Q34341056 | ||
N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets | Q34370823 | ||
Role of sphingosine kinase 2 in cell migration toward epidermal growth factor | Q34425898 | ||
Alkaline sphingomyelinase: an old enzyme with novel implications | Q34516413 | ||
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. | Q34546048 | ||
Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. | Q34652231 | ||
Ceramidases in the regulation of ceramide levels and function | Q34661426 | ||
Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites | Q35048357 | ||
Egress: a receptor-regulated step in lymphocyte trafficking | Q35216962 | ||
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. | Q35804361 | ||
Endothelial cell barrier regulation by sphingosine 1-phosphate | Q35838988 | ||
Mechanisms of cardioprotection by lysophospholipids | Q35838996 | ||
Biologically active sphingolipids in cancer pathogenesis and treatment | Q35852313 | ||
Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors | Q35873296 | ||
Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist | Q35978652 | ||
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. | Q36056673 | ||
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs | Q36072414 | ||
Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1 | Q36117441 | ||
Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network | Q36184401 | ||
Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival | Q36256204 | ||
Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation | Q36267274 | ||
Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis | Q36399383 | ||
Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine | Q36434460 | ||
Antitumor activity of sphingosine kinase inhibitors | Q40288624 | ||
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages | Q40306295 | ||
Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. | Q40310350 | ||
Sphingosine kinase 1 is up-regulated in colon carcinogenesis | Q40345686 | ||
Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. | Q40352532 | ||
The mechanism of membrane targeting of human sphingosine kinase 1. | Q40358838 | ||
Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells | Q40367377 | ||
Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines | Q40384186 | ||
S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate | Q40405662 | ||
Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells | Q40533285 | ||
Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. | Q40584948 | ||
The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation | Q40763807 | ||
Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis | Q40777268 | ||
Sphingosine kinase-mediated calcium signaling by muscarinic acetylcholine receptors. | Q40801018 | ||
An oncogenic role of sphingosine kinase | Q40837836 | ||
Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. | Q40845943 | ||
Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis | Q40914150 | ||
Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. | Q41656945 | ||
Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions | Q42090948 | ||
N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. | Q42461110 | ||
Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate | Q42556020 | ||
Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens | Q42805681 | ||
SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism | Q42810891 | ||
The signal modulator protein 14-3-3 is a target of sphingosine- or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells | Q42820452 | ||
Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools | Q42952142 | ||
Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma | Q43601724 | ||
S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus | Q43692744 | ||
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients | Q43931513 | ||
Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes | Q44091518 | ||
Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate | Q44172187 | ||
Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells | Q44368643 | ||
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment | Q44370378 | ||
Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. | Q44385104 | ||
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. | Q44482860 | ||
Sphingosine kinase transmits estrogen signaling in human breast cancer cells. | Q44526063 | ||
Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis | Q44572814 | ||
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study | Q44616726 | ||
Clostridium perfringens alpha-toxin activates the sphingomyelin metabolism system in sheep erythrocytes | Q44711006 | ||
The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors | Q44722923 | ||
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate | Q44734550 | ||
Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney | Q44916450 | ||
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. | Q44987202 | ||
Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis | Q45004851 | ||
Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. | Q45086529 | ||
Lung injury: sphingosine-1-phosphate to the rescue | Q45124288 | ||
Attenuation of shock-induced acute lung injury by sphingosine kinase inhibition | Q45173949 | ||
Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression | Q45215121 | ||
KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts | Q45218848 | ||
Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. | Q45259405 | ||
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. | Q45262225 | ||
Sphingosine-1-phosphate receptor expression in cardiac fibroblasts is modulated by in vitro culture conditions | Q46061167 | ||
Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. | Q46117845 | ||
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients | Q46265539 | ||
Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry | Q46377682 | ||
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate | Q46494392 | ||
Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue | Q46516547 | ||
Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration | Q46620860 | ||
Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin | Q46728817 | ||
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. | Q46751827 | ||
Suppression of mast cell degranulation by a novel ceramide kinase inhibitor, the F-12509A olefin isomer K1. | Q46849690 | ||
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models | Q46853200 | ||
Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner | Q46863524 | ||
Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor | Q46927225 | ||
Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model | Q46968445 | ||
Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine | Q46978325 | ||
A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. | Q46979859 | ||
Enzymatic measurement of sphingosine 1-phosphate | Q48163685 | ||
Multiple actions of dimethylsphingosine in 1321N1 astrocytes. | Q48186524 | ||
Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. | Q48415894 | ||
Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways | Q48528203 | ||
Activation of casein kinase II by sphingosine. | Q48623665 | ||
B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination | Q48744563 | ||
Erythrocytes store and release sphingosine 1-phosphate in blood. | Q51084957 | ||
Sphingomyelin synthesis in rat liver occurs predominantly at the cis and medial cisternae of the Golgi apparatus. | Q52483696 | ||
Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of immunostimulatory activity in murine bone marrow-derived dendritic cells. | Q53577932 | ||
Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. | Q53624480 | ||
S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. | Q54611404 | ||
A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts. | Q54672484 | ||
Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes | Q57952121 | ||
FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia | Q63431636 | ||
Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities | Q69113678 | ||
Programmed cell death induced by ceramide | Q70619078 | ||
Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents | Q72035556 | ||
Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum | Q73436742 | ||
Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart | Q73571790 | ||
A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples | Q73881103 | ||
F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete | Q74044934 | ||
Ceramide and apoptosis | Q77875070 | ||
Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation | Q79150735 | ||
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation | Q79468611 | ||
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects | Q79581116 | ||
The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis | Q79905421 | ||
Sphingosine kinase inhibitor suppresses dendritic cell migration by regulating chemokine receptor expression and impairing p38 mitogen-activated protein kinase | Q80145738 | ||
High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor | Q80284338 | ||
A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury | Q80567231 | ||
Sphingosine 1-phosphate accelerates wound healing in diabetic mice | Q80648055 | ||
A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis | Q80730157 | ||
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study | Q83984696 | ||
P433 | issue | 2 | |
P304 | page(s) | 181-195 | |
P577 | publication date | 2008-06-13 | |
P1433 | published in | Pharmacological Reviews | Q2085079 |
P1476 | title | "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets | |
P478 | volume | 60 |
Q41661043 | "Dicing and Splicing" Sphingosine Kinase and Relevance to Cancer. |
Q33598692 | 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. |
Q61942652 | A Circadian Rhythm in both Complement Cascade (ComC) Activation and Sphingosine-1-Phosphate (S1P) Levels in Human Peripheral Blood Supports a Role for the ComC-S1P Axis in Circadian Changes in the Number of Stem Cells Circulating in Peripheral Blood |
Q41972670 | A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells |
Q33855120 | A novel function of sphingosine kinase 1 suppression of JNK activity in preventing inflammation and injury |
Q33988392 | A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders |
Q27009351 | A review of ceramide analogs as potential anticancer agents |
Q41931868 | ABC294640, a novel sphingosine kinase 2 inhibitor induces oncogenic virus infected cell autophagic death and represses tumor growth |
Q52663621 | ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. |
Q42386819 | AICAR inhibits ceramide biosynthesis in skeletal muscle |
Q39026397 | ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model |
Q30827729 | Ablation of Sphingosine 1-Phosphate Receptor Subtype 3 Impairs Hippocampal Neuron Excitability In vitro and Spatial Working Memory In vivo |
Q30303094 | Abluminal stimulation of sphingosine 1-phosphate receptors 1 and 3 promotes and stabilizes endothelial sprout formation |
Q35522175 | Activated platelets release sphingosine 1-phosphate and induce hypersensitivity to noxious heat stimuli in vivo. |
Q90228330 | Activation of the Sphingosine 1 Phosphate-Rho Pathway in Pterygium and in Ultraviolet-Irradiated Normal Conjunctiva |
Q34125349 | Adiponectin signaling in the liver |
Q34137322 | Advances in the management of peritoneal mesothelioma |
Q36664563 | Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. |
Q46135175 | Altered Leukocyte Sphingolipid Pathway in Breast Cancer. |
Q45065681 | An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors. |
Q37076525 | Analysis of inflammatory and lipid metabolic networks across RAW264.7 and thioglycolate-elicited macrophages |
Q36049681 | Analysis of sphingosine kinase activity in single natural killer cells from peripheral blood. |
Q52684278 | Anti-CD69 therapy induces rapid mobilization and high proliferation of HSPCs through S1P and mTOR. |
Q36374498 | Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model |
Q35011925 | Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma |
Q47232359 | Apolipoprotein M Inhibits Angiogenic and Inflammatory Response by Sphingosine 1-Phosphate on Retinal Pigment Epithelium Cells. |
Q42701208 | Arsonists and firefighters: the perpetual inflammatory civil war for survival |
Q27000801 | Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) |
Q55030990 | Autophagy and Its Interaction With Intracellular Bacterial Pathogens. |
Q35945545 | BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. |
Q34020834 | Basal release of ATP: an autocrine-paracrine mechanism for cell regulation |
Q27667249 | Biochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal Antibody |
Q28486289 | Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent |
Q36830558 | Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells |
Q41089511 | Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis |
Q33593619 | Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects |
Q35897043 | Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells. |
Q64904602 | Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy. |
Q41533503 | Ceramide and insulin resistance: how should the issue be approached? |
Q55002300 | Ceramide species are elevated in human breast cancer and are associated with less aggressiveness. |
Q38124070 | Ceramides in the pathophysiology of the anterior segment of the eye. |
Q30361278 | Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. |
Q28483643 | Characterization of isoenzyme-selective inhibitors of human sphingosine kinases |
Q42397403 | Characterization of sphingosine-1-phosphate lyase activity by electrospray ionization-liquid chromatography/tandem mass spectrometry quantitation of (2E)-hexadecenal |
Q40080527 | Cigarette smoke inhibits efferocytosis via deregulation of sphingosine kinase signaling: reversal with exogenous S1P and the S1P analogue FTY720. |
Q47996348 | Classification of sphingosine kinase inhibitors using counter propagation artificial neural networks: A systematic route for designing selective SphK inhibitors |
Q41622885 | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
Q54662271 | Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting. |
Q28250778 | Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression |
Q34399068 | Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids |
Q38619642 | DNA damage response and sphingolipid signaling in liver diseases |
Q37415213 | Dendritic cell sphingosine-1-phosphate lyase regulates thymic egress |
Q30417604 | Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors |
Q39517521 | Determination of sphingosine kinase 2 activity using fluorescent sphingosine by capillary electrophoresis |
Q22305854 | Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach |
Q89847027 | Differential contribution of sensory transient receptor potential channels in response to the bioactive lipid sphingosine-1-phosphate |
Q48455938 | Differential modulation of S1PR(1-5) and specific activities of SphK and nSMase in pulmonary and cerebral tissues of rats exposed to hypobaric hypoxia |
Q58772957 | Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity |
Q34555185 | Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels |
Q37830235 | Dissecting the role of the S1P/S1PR axis in health and disease. |
Q52671501 | Divergent Role of Sphingosine 1-Phosphate in Liver Health and Disease. |
Q45071199 | Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. |
Q39648906 | Dupuytren's Fibroblast Contractility by Sphingosine-1-Phosphate Is Mediated Through Non-Muscle Myosin II |
Q35078615 | Effects of inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate induced insulin resistance in L6 myotubes |
Q58751451 | Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO |
Q37341131 | Emerging Role of Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis |
Q37965547 | Emerging oral drugs for relapsing-remitting multiple sclerosis. |
Q35975127 | Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy |
Q48158764 | Endurance training selectively increases high-density lipoprotein-bound sphingosine-1-phosphate in the plasma |
Q39774569 | Enhancement of sphingosine kinase 1 catalytic activity by deletion of 21 amino acids from the COOH-terminus |
Q51147812 | Enhancement of wound closure by modifying dual release patterns of stromal-derived cell factor-1 and a macrophage recruitment agent from gelatin hydrogels. |
Q39577061 | Enigmol: a novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer |
Q34104555 | Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers |
Q36748690 | Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer |
Q33796082 | Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. |
Q53084249 | Exogenous sphingosine 1-phosphate protects murine splenocytes against hypoxia-induced injury. |
Q37408557 | Export and functions of sphingosine-1-phosphate. |
Q27009557 | Export of sphingosine-1-phosphate and cancer progression |
Q35889923 | Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer |
Q36320677 | Expression of sphingosine 1-phosphate receptors in the rat dorsal root ganglia and defined single isolated sensory neurons |
Q34183703 | Extracellular and Intracellular Actions of Sphingosine-1-Phosphate |
Q34162587 | FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells |
Q35819965 | FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans |
Q33854428 | FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. |
Q34718530 | FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. |
Q34551954 | Fenretinide causes emphysema, which is prevented by sphingosine 1-phoshate |
Q37765473 | Fingolimod is a potential novel therapy for multiple sclerosis |
Q48649157 | Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide |
Q37851885 | Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis |
Q98471366 | Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase |
Q43984955 | Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer |
Q90296101 | Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis |
Q33831886 | Genetic evidence for involvement of neuronally expressed S1P₁ receptor in nociceptor sensitization and inflammatory pain |
Q39624007 | Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants |
Q35845653 | Growth and metabolism of Beauveria bassiana spores and mycelia |
Q35238369 | High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists |
Q40964594 | High levels of sphingolipids in human breast cancer. |
Q40567317 | Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis |
Q38307041 | Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis |
Q37233204 | Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor |
Q42966392 | Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. |
Q36898368 | Implication of sphingosin-1-phosphate in cardiovascular regulation |
Q37662940 | Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis |
Q38162168 | Inflammatory and microenvironmental factors involved in breast cancer progression |
Q35661331 | Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel |
Q88990558 | Innate lymphoid cells-key immune integrators of overall body homeostasis |
Q34373466 | Interdiction of sphingolipid metabolism to improve standard cancer therapies |
Q92630730 | Interleukin-22 Mediates the Chemotactic Migration of Breast Cancer Cells and Macrophage Infiltration of the Bone Microenvironment by Potentiating S1P/SIPR Signaling |
Q33386012 | Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection |
Q37100281 | Interstitial Fluid Sphingosine-1-Phosphate in Murine Mammary Gland and Cancer and Human Breast Tissue and Cancer Determined by Novel Methods |
Q28743138 | Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: role of sphingosine kinase 1 and S1P lyase |
Q34053079 | Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate |
Q35830897 | Inverse-phosphocholine lipids: a remix of a common phospholipid |
Q36369205 | Involvement of Band3 in the efflux of sphingosine 1-phosphate from erythrocytes |
Q46049440 | Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone |
Q40341970 | Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)? |
Q39565607 | KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity. |
Q36607525 | Legionella pneumophila S1P-lyase targets host sphingolipid metabolism and restrains autophagy |
Q92257208 | Light Stress-Induced Increase of Sphingosine 1-Phosphate in Photoreceptors and Its Relevance to Retinal Degeneration |
Q37173179 | Lipid phosphate phosphatases and signaling |
Q28088430 | Lipid phosphate phosphatases and their roles in mammalian physiology and pathology |
Q34269858 | Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. |
Q91823189 | Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia |
Q37414484 | Lyase to live by: sphingosine phosphate lyase as a therapeutic target |
Q34084937 | Lymphangiogenesis: A new player in cancer progression |
Q47233200 | Lysophosphatidic Acid Signaling Axis Mediates Ceramide 1-Phosphate-Induced Proliferation of C2C12 Myoblasts |
Q99418917 | MYPT1 O-GlcNAc modification regulates sphingosine-1-phosphate mediated contraction |
Q97644512 | Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome |
Q33829692 | Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget |
Q92961499 | Manipulation of the Sphingolipid Rheostat Influences the Mediator of Flow-Induced Dilation in the Human Microvasculature |
Q37457462 | Maternal fumonisin exposure as a risk factor for neural tube defects |
Q37154242 | Mechanisms linking obesity and cancer |
Q36377252 | Mechanisms of lipotoxicity in the cardiovascular system |
Q38713803 | Mechanisms of sphingosine-1-phosphate-mediated vasoconstriction of rat afferent arterioles |
Q30413877 | Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development |
Q42120428 | MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma |
Q33636763 | Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. |
Q93335813 | Molecular mechanisms of biogenesis of apoptotic exosome-like vesicles and their roles as damage-associated molecular patterns |
Q41829826 | Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. |
Q36355889 | Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids |
Q28078299 | NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications |
Q41127962 | NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
Q35955451 | Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer |
Q37588466 | Noncanonical transforming growth factor beta signaling in scleroderma fibrosis |
Q33684331 | Normalization of diabetic wound healing |
Q92012755 | Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases |
Q37925819 | Nuclear sphingolipid metabolism |
Q38092176 | Oncogenic properties of sphingosine kinases in haematological malignancies. |
Q43838770 | Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system |
Q87417830 | Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice |
Q36996563 | Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management |
Q64076938 | Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2 |
Q37660877 | Outside the box signaling: secreted factors modulate GnRH receptor-mediated gonadotropin regulation |
Q36410748 | Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice |
Q38960964 | Oxidized LDL-induced angiogenesis involves sphingosine 1-phosphate: prevention by anti-S1P antibody |
Q45073187 | Paradoxical Association of Postoperative Plasma Sphingosine-1-Phosphate with Breast Cancer Aggressiveness and Chemotherapy. |
Q44324305 | Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model |
Q35130512 | Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system |
Q38763707 | Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications |
Q37782076 | Polymer-drug conjugates for novel molecular targets |
Q37002064 | Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial-mesenchymal transition in cancer |
Q88961948 | Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells |
Q37658857 | Radiation countermeasure agents: an update |
Q35101294 | Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. |
Q34559806 | Regulating survival and development in the retina: key roles for simple sphingolipids |
Q35683960 | Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes |
Q37415111 | Regulation of vascular physiology and pathology by the S1P2 receptor subtype. |
Q57802697 | Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse |
Q38262594 | Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease |
Q34574599 | Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats |
Q90341490 | Role of Bioactive Sphingolipids in Inflammation and Eye Diseases |
Q58760187 | Role of S1P/S1PR3 axis in release of CCL20 from human bronchial epithelial cells |
Q92009926 | Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma |
Q40990718 | Role of Sphingosine-1-Phosphate in Transplant Vasculopathy Evoked by Anti-HLA Antibody |
Q64891856 | Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke. |
Q39506935 | Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells |
Q34879183 | Roles of sphingosine 1-phosphate on tumorigenesis |
Q37699303 | Roles of sphingosine-1-phosphate in reproduction |
Q91738678 | Roles of sphingosine-1-phosphate signaling in cancer |
Q39169246 | Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis. |
Q38626918 | S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such as IL-1β or Lipocalin-2. |
Q35136728 | S1P is associated with protection in human and experimental cerebral malaria |
Q33886533 | S1P metabolism in cancer and other pathological conditions |
Q42735904 | S1P promotes breast cancer progression by angiogenesis and lymphangiogenesis |
Q48849226 | S1P prophylaxis mitigates acute hypobaric hypoxia-induced molecular, biochemical, and metabolic disturbances: A preclinical report |
Q38703649 | S1P receptor 1-Mediated Anti-Renin-Angiotensin System Cardioprotection: Pivotal Role of Mast Cell Aldehyde Dehydrogenase Type 2. |
Q35633763 | S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection |
Q91782570 | S1P-S1PR1 Signaling: the "Sphinx" in Osteoimmunology |
Q92914007 | SGPL1321 mutation: one main trigger for invasiveness of pediatric alveolar rhabdomyosarcoma |
Q37997376 | Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. |
Q34345362 | Single-cell sphingosine kinase activity measurements in primary leukemia |
Q35776618 | Sources, metabolism, and regulation of circulating sphingosine-1-phosphate |
Q35138620 | Space radiation-associated lung injury in a murine model |
Q92347503 | Sphingolipid metabolism and drug resistance in ovarian cancer |
Q89977951 | Sphingolipids and Mitochondrial Dynamic |
Q45072496 | Sphingolipids and Redox Signaling in Renal Regulation and Chronic Kidney Diseases |
Q64965708 | Sphingolipids as Emerging Mediators in Retina Degeneration. |
Q37527497 | Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system |
Q26773230 | Sphingolipids in High Fat Diet and Obesity-Related Diseases |
Q49972804 | Sphingolipids role in the regulation of inflammatory response: From leukocyte biology to bacterial infection |
Q47095059 | Sphingosine 1-Phosphate- and C-C Chemokine Receptor 2-Dependent Activation of CD4+ Plasmacytoid Dendritic Cells in the Bone Marrow Contributes to Signs of Sepsis-Induced Immunosuppression |
Q36636026 | Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways |
Q35921615 | Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells |
Q34121255 | Sphingosine 1-phosphate and cancer |
Q38223679 | Sphingosine 1-phosphate and cancer: lessons from thyroid cancer cells |
Q34474499 | Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype |
Q36532321 | Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor |
Q27024207 | Sphingosine 1-phosphate signaling pathway in inner ear biology. New therapeutic strategies for hearing loss? |
Q41980318 | Sphingosine 1-phosphate to p38 signaling via S1P1 receptor and Gαi/o evokes augmentation of capsaicin-induced ionic currents in mouse sensory neurons. |
Q38185438 | Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy? |
Q47121464 | Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer |
Q30275552 | Sphingosine Kinase 2 Deficiency Attenuates Kidney Fibrosis via IFN-γ. |
Q35845319 | Sphingosine Kinase 2 and Ceramide Transport as Key Targets of the Natural Flavonoid Luteolin to Induce Apoptosis in Colon Cancer Cells |
Q42233131 | Sphingosine analog AAL-R promotes activation of LCMV-infected dendritic cells |
Q33727889 | Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro |
Q42149287 | Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways |
Q54565672 | Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. |
Q38937332 | Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer |
Q27303619 | Sphingosine kinase 1 deficiency exacerbates LPS-induced neuroinflammation |
Q45070648 | Sphingosine kinase 1 in breast cancer |
Q38013700 | Sphingosine kinase 1 in viral infections. |
Q39168123 | Sphingosine kinase 1 overexpression stimulates intestinal epithelial cell proliferation through increased c-Myc translation |
Q38333309 | Sphingosine kinase 1/S1P pathway involvement in the GDNF-induced GAP43 transcription |
Q46726983 | Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis |
Q64933352 | Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo. |
Q37328806 | Sphingosine kinase regulation and cardioprotection |
Q33586246 | Sphingosine kinase-1 (SphK-1) regulates Mycobacterium smegmatis infection in macrophages |
Q37208958 | Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human |
Q43269484 | Sphingosine kinase-1: a potential mediator of renal fibrosis |
Q89987678 | Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1 |
Q35204641 | Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells |
Q38408286 | Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells |
Q38115668 | Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system? |
Q37405258 | Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expression |
Q91801206 | Sphingosine-1-Phosphate Facilitates Skin Wound Healing by Increasing Angiogenesis and Inflammatory Cell Recruitment with Less Scar Formation |
Q35996098 | Sphingosine-1-Phosphate Lyase Deficient Cells as a Tool to Study Protein Lipid Interactions |
Q26766425 | Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential |
Q26775993 | Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation |
Q35059057 | Sphingosine-1-phosphate acting via the S1P₁ receptor is a downstream signaling pathway in ceramide-induced hyperalgesia |
Q34474363 | Sphingosine-1-phosphate and immune regulation: trafficking and beyond |
Q37176189 | Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts |
Q26852824 | Sphingosine-1-phosphate in chronic intestinal inflammation and cancer |
Q37543777 | Sphingosine-1-phosphate in the lymphatic fluid determined by novel methods |
Q34251293 | Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. |
Q38953409 | Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation |
Q91863467 | Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain |
Q37726630 | Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo |
Q35146069 | Sphingosine-1-phosphate receptor 2 |
Q35121901 | Sphingosine-1-phosphate receptor 3 mediates sphingosine-1-phosphate induced release of weibel-palade bodies from endothelial cells. |
Q30435328 | Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS |
Q50861734 | Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension. |
Q37358457 | Sphingosine-1-phosphate synthesis and functions in mast cells |
Q42181059 | Sphingosine-1-phosphate transporters as targets for cancer therapy. |
Q48547561 | Sphingosine-1-phosphate, regulated by FSH and VEGF, stimulates granulosa cell proliferation. |
Q46119380 | Sphingosine-1-phosphate-induced nociceptor excitation and ongoing pain behavior in mice and humans is largely mediated by S1P3 receptor |
Q50665340 | Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma. |
Q90117111 | Sphingosine-1-phosphate: From insipid lipid to a key regulator |
Q37697043 | Sphk1 promotes breast epithelial cell proliferation via NF-κB-p65-mediated cyclin D1 expression |
Q28482973 | StarD7 knockdown modulates ABCG2 expression, cell migration, proliferation, and differentiation of human choriocarcinoma JEG-3 cells |
Q89162813 | Survival benefit of sphingosin-1-phosphate and receptors expressions in breast cancer patients |
Q37501281 | Symbiont-derived sphingolipids modulate mucosal homeostasis and B cells in teleost fish |
Q37397209 | Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro |
Q91713570 | T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? |
Q35831148 | TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis |
Q35935087 | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
Q42380774 | Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation |
Q37172893 | Targeting SphK1 as a new strategy against cancer |
Q57399036 | Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss |
Q37894772 | Targeting sphingosine-1-phosphate receptors in cancer |
Q39379449 | Targeting sphingosine-1-phosphate signaling for cancer therapy |
Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
Q34217756 | The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. |
Q26748848 | The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined |
Q27657731 | The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen |
Q62272072 | The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension |
Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
Q34094557 | The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage |
Q37688434 | The interplay between bioactive sphingolipids and steroid hormones |
Q36011196 | The outs and the ins of sphingosine-1-phosphate in immunity |
Q37319760 | The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. |
Q38694191 | The role of Lutheran/basal cell adhesion molecule in human bladder carcinogenesis. |
Q34271986 | The role of adiponectin in cancer: a review of current evidence |
Q45051424 | The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice |
Q36241051 | The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. |
Q57153732 | The role of sphingosine-1-phosphate in inflammation and cancer progression |
Q38734489 | The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications. |
Q38909010 | The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. |
Q34379689 | The sphingosine 1-phosphate receptor, S1PR₁, plays a prominent but not exclusive role in enhancing the excitability of sensory neurons |
Q34986940 | The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension |
Q48349932 | The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. |
Q39251134 | The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism |
Q39253082 | The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia |
Q38915115 | Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism |
Q34527281 | Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer |
Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
Q38909416 | Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. |
Q37071804 | Transcriptional modulation of SLC26A3 (DRA) by sphingosine-1-phosphate. |
Q59354243 | Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice |
Q33635116 | Twofer anti-vascular therapy targeting sphingosine-1-phosphate for breast cancer. |
Q30353137 | Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. |
Q37293908 | Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation |
Q39005334 | Vitamin D therapy in experimental allergic encephalomyelitis could be limited by opposing effects of sphingosine 1-phosphate and gelsolin dysregulation. |
Q33773550 | Why is effective treatment of asthma so difficult? An integrated systems biology hypothesis of asthma |
Q51831879 | β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. |